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Apneusis responding to buspirone in multiple sclerosis
RJ O’Sullivan1, IG Brown2 and MP Pender1,3
Apneusis is a disturbance of respiratory rhythm characterized by severely prolonged inspiratory effort,
and is caused by bilateral lesions in the dorsal pons. In humans it is most commonly caused by pon-
tine infarction and has rarely been reported in multiple sclerosis (MS). Here we report on a patient
with MS who developed episodic apneusis which responded to treatment with buspirone, a serotonin
type 1A receptor agonist. Multiple Sclerosis 2008; 14: 705–707. http://msj.sagepub.com
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Introduction
Apneustic breathing is defined as the arrest of respi-
ration in tonic inspiration [1] and reflects a dis-
turbed inspiratory off-switch mechanism leading
to a delayed transition from the inspiratory phase
to the expiratory phase of respiration [2]. In experi-
mental animals as well as in humans, apneusis is
associated with lesions involving both sides of the
dorsal pons, especially the lateral pontine tegmen-
tum [1]. Clinically, apneustic breathing is a sign of
great localizing value and usually denotes pontine
infarction due to basilar artery occlusion, although
it may also occur with other pathology involving
the dorsal pons [3]. Apneusis has rarely been
reported in patients with multiple sclerosis (MS)
[4]. Here we report on a patient with MS who devel-
oped episodic apneusis which responded to treat-
ment with buspirone, a 5-hydroxytryptamine (sero-
tonin) type 1A (5-HT1A) receptor agonist.
Case report
A 44-year-old woman with relapsing–remitting MS
with onset in 1985 presented, in December 2006,
with episodes of breathing difficulty requiring
admission to hospital. Her most recent relapse had
been in August 2005 when she developed increased
unsteadiness of gait, increased upper limb tremor
and swallowing difficulty requiring the insertion
of a percutaneous endoscopic gastrostomy tube. In
retrospect she thought that her episodes of breath-
ing difficulty had been occurring for approximately
4 years, with the onset having no clear relationship
to a relapse, and with progressive worsening over
the 18 months prior to presentation. By the time
of presentation her episodes of breathing difficulty
had become sufficiently severe as to result in cyano-
sis and collapse, requiring transient positive pres-
sure ventilation with a bag and mask apparatus to
terminate the episodes and restore spontaneous
ventilation.
The episodes of breathing difficulty were noted
by the patient to be sometimes triggered by singing,
laughing, prolonged talking, physical exercise and
hot showers. She described a sensation of being
unable to breathe in or out; direct observation of
these episodes in hospital revealed cessation of the
respiratory cycle in full inspiration, with no airways
noise or stridor and no chest wall or abdominal
excursion to suggest ongoing respiratory effort
against an upper airway obstruction. On a number
of occasions oxygen saturation as measured by
pulse oximetry was significantly reduced, some-
times below 80% (normal ≥94%), and cyanosis
was observed, with or without loss of conscious-
ness. Episodes resolving spontaneously ended with
a forceful expiration. Her breathing difficulties were
consistent with episodic apneusis.
At the time of admission to hospital her medica-
tion comprised interferon β-1b 8 × 106 IU by subcu-
taneous injection on alternate days, gabapentin
300 mg three times daily, baclofen 15 mg four
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times daily, omeprazole 20 mg daily, fluoxetine
40 mg daily, oxybutynin 5 mg twice daily, docusate
sodium with sennosides 100 mg/16 mg daily and a
cranberry tablet once daily.
Neurological examination revealed titubation of
the head and a pathologically brisk jaw jerk. Cranial
nerve examination was otherwise normal, and lar-
yngoscopy demonstrated normal anatomy and
movement of the vocal cords. On examination of
the upper limbs there was a bilateral mild proximal
coarse postural (wing-beating) tremor. Power was
mildly reduced proximally and bilaterally. The
deep tendon reflexes in the upper limbs were path-
ologically brisk and there was marked ataxia and
intention tremor bilaterally. Vibration sense and
proprioception were normal. In the lower limbs
there was bilateral mild weakness affecting flexors
more than extensors, the deep tendon reflexes
were pathologically brisk and the plantar responses
were extensor. Coordination was impaired bilater-
ally, worse on the left. Vibration sense was reduced
in the left toes, and proprioception was impaired in
the toes bilaterally. She had a spastic ataxic gait. Her
Kurtzke Expanded Disability Status Scale score was
6.5.
A plain chest radiograph was normal and arterial
blood gases between events showed no abnormal-
ity. On pulmonary function testing, spirometry
was normal, as were the maximal inspiratory and
expiratory pressures. A magnetic resonance imaging
(MRI) brain scan at this time showed multiple cere-
bral white matter lesions, including periventricular
lesions, which were hyperintense on fluid-
attenuated inversion recovery imaging. There were
bilateral lesions in the dorsal pons, particularly
involving the lateral pontine tegmentum (Figure 1),
but there were no lesions in the medulla.
Treatment with oral buspirone was commenced
3 weeks after admission to hospital at a dose of
5 mg twice daily and gradually increased to 20 mg
three times daily. Dose increases were made cau-
tiously because of the potential risk of serotonin
syndrome as the patient was also taking fluoxetine
40 mg daily. The occurrence of apneustic episodes
decreased after commencement of buspirone, and
major apneustic episodes ceased completely
2 weeks after reaching the 60 mg daily dose (Fig-
ure 2). After 13 weeks in hospital, she was dis-
charged to a nursing home. There she continued
to experience minor transient respiratory rhythm
disturbances which sometimes required positive
pressure ventilation with a bag and mask for several
breaths. On two occasions she experienced a recur-
rence of major apneustic episodes triggered by fever
associated with urinary tract infections.
Discussion
Our patient with established relapsing–remitting
MS presented with episodes of apneusis which are
explained by the bilateral lesions in her dorsal pons.
To our knowledge there are only two other reported
cases of apneusis in patients with MS [4]. Experi-
mentation in rats has shown that excitation of the
Kölliker–Fuse nuclei in the dorsolateral pons results
in activation of postinspiratory neurons which
Figure 1 MRI brain scan axial proton density image show-
ing bilateral lesions involving the dorsal pons, particularly the
lateral pontine tegmentum (arrows).
Figure 2 Frequency of major episodes of respiratory diffi-
culty before and after treatment with buspirone, from the
time of admission to hospital until the time of discharge.
Major episodes of respiratory difficulty were defined by the
occurrence of one or more of the following: loss of con-
sciousness; cyanosis; arterial oxygen saturation under 94%;
and intervention with manual ventilation. The times of initia-
tion and escalation of the daily dose of buspirone are indi-
cated by arrows.
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switch off inspiration; conversely, inhibition of the
Kölliker–Fuse nuclei triggers apneusis [2]. Thus, the
apneustic breathing in our patient could be
explained either by involvement of the Kölliker–
Fuse nuclei or of efferent pathways from these
nuclei in the dorsolateral pons.
As apneustic respiratory patterns in experimental
animals can be abolished by administration of 5-
HT1A receptor agonists [5], this treatment was suc-
cessfully trialed in a child with severe apneusis fol-
lowing neurosurgery for an astrocytoma in the pons
and medulla oblongata [6]. Subsequently it has also
been used successfully in a patient with apneusis
due to brainstem infarction [7], but to our knowl-
edge has not been used to treat apneusis due to MS.
In conclusion, our case emphasizes the impor-
tance of distinguishing between apneusis and
other respiratory complications of MS, because
apneusis may be amenable to treatment with 5-
HT1A receptor agonists such as buspirone.
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